Benzenesulfonyl-lactams and their use as active substances of pharmaceutical compositions
The invention relates to new medicaments which present an activity upon the central nervous system, particularly psychotrope, with modifications of the behaviour and which contain, as active substance, chemical compounds the basic structure of which is of the benzenesulfonyl-lactam type, as well as their salts obtained with physiologically acceptable acids. 
     In the text, the term &#34;medicament&#34; designates any pharmaceutical composition, which contains one at least of the chemical compounds hereafter defined, in association with a pharmaceutically acceptable carrier. 
     The invention also relates to new compounds which constitute the active substance of the new compounds. 
     The invention also relates to a process for preparing the above said chemical compounds. 
     Benzenesulfonyl-lactams of formula: ##STR2## in which R represents (R 2 ) n  C 6  H 5-n  (CH 2 ) m  --, R 2  representing H, an alkyl radical, an alkoxy radical, a halogen atom or a nitro group, n is varying from 1 to 5, m has the value of 0 or 1, Z can represent SO 2 , are mentioned in the Chemical Abstracts, vol. 94, No. 156735v, 1981, p. 642. 
     The compounds are presented as quality improvers for citrus fruits. 
     The new medicaments according to the invention are characterized by the fact that they contain, as active substance, at least one of the compounds corresponding to the following general formula (I): ##STR3## in which: X represents a hydrogen atom, an alkoxy group from 1 to 4 carbon atoms; 
     Y represents a hydrogen atom, a CF 3  or NO 2  group; 
     Z represents a hydrogen atom, halogen, an alkoxy group from 1 to 4 carbon atoms, a NO 2  group; 
     W represents a hydrogen atom, halogen, a CF 3  group, a NO 2  group, an alkoxy group from 1 to 4 carbon atoms; n is 1, 2 or 3; 
     R 1  represents a hydrogen atom, an alkyl group from 1 to 6 carbon atoms; 
     R 2  represents a hydrogen atom, an OH group, an OR group in which R represents an alkyl group from 1 to 4 carbon atoms or an acyl group from 1 to 6 carbon atoms; provided that X or Z represents an alkoxy group from 1 to 4 carbon atoms or Y represents the CF 3  or NO 2  group. 
     This group will be designated by G1 in the following. 
     A preferred group of medicaments according to the invention is constituted by those the active substance of which is a compound of formula (I): ##STR4## in which: X represents a hydrogen atom, an alkoxy group from 1 to 4 carbon atoms; 
     Y represents a hydrogen atom, a CF 3  group, a NO 2  group; 
     Z represents a hydrogen atom, halogen, an alkoxy group from 1 to 4 carbon atoms, a NO 2  group; 
     W represents a hydrogen atom, halogen, a CF 3  group, a NO 2  group, an alkoxy group from 1 to 4 carbon atoms; 
     n is 1, 2 or 3; 
     R 1  represents a hydrogen atom, an alkyl group from 1 to 6 carbon atoms; 
     R 2  represents a hydrogen atom, an OH group, an OR group in which R represents an alkyl group from 1 to 4 carbon atoms or an acyl group from 1 to 6 carbon atoms; provided that when n is 1: 
     Y or W represents a CF 3  group; and when n is 2 or 3: 
     X or Z represents an alkoxy group from 1 to 4 carbon atoms or Y represents the CF 3  or NO 2  group. 
     This group will be designated in the following by G1bis. 
     A preferred group of medicaments according to the invention is constituted by those the active substance of which is a compound of formula (I) in which n is 1 and corresponds to the following formula (II): ##STR5## 
     This group will be designated in the following by G2. 
     Another preferred group of medicaments according to the invention is constituted by those the active substance of which is a compound of formula (I) in which n is 2 and corresponds to the following formula (III): ##STR6## 
     This group will be designated in the following by G3. 
     Another preferred group of medicaments according to the invention is constituted by those the active substance of which is a compound of formula (I) in which n is 3 and corresponds to the following formula (IV): ##STR7## 
     This group will be designated in the following by G4. 
     Another preferred group of medicaments according to the invention is constituted by those the active substance of which is a compound of formula (I) in which R 1  represents H or CH 3 . 
     This group will be designated in the following by G5. 
     Another preferred group of medicaments according to the invention is constituted by those the active substance of which is a compound of formula (I) in which R 2  represents H, OH or OCOCH 3 . 
     This group will be designated in the following by G6. 
     Another preferred group of medicaments according to the invention is constituted by those the active substance of which is a compound of formula (I) in which Y represents CF 3 , X represents H, and corresponding to the following formula (VII): ##STR8## and in which Z represents H or Cl and W represents H or CF 3 . 
     This group will be designated in the following by G7. 
     Among group G7, a preferred group of medicaments according to the invention is constituted by those the active substance of which is a compound of formula (I) in which Z represents H and W represents CF 3  and corresponding to the following formula (VIII): ##STR9## 
     This group will be designated in the following by G8. 
     Among the group G7, another preferred group of medicaments according to the invention is constituted by those the active substance of which is a compound of formula (I) in which Z represents Cl and W represents H and corresponding to the following formula (IX): ##STR10## 
     This group will be designated in the following by G9. 
     Another preferred group of medicaments according to the invention is constituted by those the active substance of which is a compound of formula (I) in which X represents OCH 3 , Y represents H and corresponding to the following formula (X): ##STR11## and in which Z represents H or OCH 3  and W represents H, Cl or OCH 3 . 
     This group will be designated in the following by G10. 
     Among group G10, a preferred group of medicaments according to the invention is constituted by those the active substance of which is a compound of formula (I) in which Z represents H and W represents Cl and corresponding to the following formula (XI): ##STR12## 
     This group will be designated in the following by G11. 
     Among group G10, a preferred group of medicaments according to the invention is constituted by those the active substance of which of formula (I) in which Z represents OCH 3  and W represents H and corresponding to the following formula (XII): ##STR13## 
     This group will be designated in the following by G12. 
     Among group G10, a preferred group of medicaments according to the invention is constituted by those the active substance of which is a compound of formula (I) in which Z represents OCH 3  and W represents OCH 3  and corresponding to the following formula (XIII): ##STR14## 
     This group will be designated in the following by G13. 
     Among group G10, another preferred group of medicaments according to the invention is constituted by those the active substance of which is a compound of formula (I) in which Z represents OCH 3  and W represents Cl and corresponding to the corresponding formula (XIV): ##STR15## 
     This group will be designated in the following by G14. 
     Another preferred group of medicaments according to the invention is constituted by those the active substance of which is a compound of formula (I) in which X represents H, Y represents H, Z represents OCH 3  and W represents H and corresponding to the following formula (XV): ##STR16## 
     This group will be designated in the following by G15. 
     Another preferred group of medicaments according to the invention is constituted by those the active substance of which is a compound of formula (I) in which Y represents NO 2  and corresponding to the following formula (XVI): ##STR17## 
     This group will be designated in the following by G16. 
     A preferred group of medicaments according to the invention is constituted by those the active substance of which is a compound of formula: 
     
         ______________________________________                                    
                  Compounds n°                                     
______________________________________                                    
 ##STR18##          1 309                                                 
 ##STR19##          1 043                                                 
 ##STR20##          1 276                                                 
 ##STR21##          1 277                                                 
 ##STR22##          1 281                                                 
 ##STR23##          1 120                                                 
 ##STR24##          1 288                                                 
 ##STR25##          1 417                                                 
 ##STR26##          1 418                                                 
 ##STR27##          1 419                                                 
 ##STR28##          1 039                                                 
______________________________________                                    
 
    
     The compounds which are the active substance of the medicaments according to the invention and which are new correspond to the general formula (I): ##STR29## in which: X represents a hydrogen atom, an alkoxy group from 1 to 4 carbon atoms; 
     Y represents a hydrogen atom, a CF 3  group, a NO 2  group; 
     Z represents a hydrogen atom, halogen, an alkoxy group from 1 to 4 carbon atoms, a NO 2  group; 
     W represents a hydrogen atom, halogen, a CF 3  group, a NO 2  group, an alkoxy group from 1 to 4 carbon atoms; 
     n is 1, 2 or 3; 
     R 1  represents a hydrogen atom, an alkyl group from 1 to 6 carbon atoms; 
     R 2  represents a hydrogen atom, an OH group, an OR group in which R represents an alkyl group from 1 to 4 carbon atoms or an acyl group from 1 to 6 carbon atoms; provided that when n is 1: 
     Y or W represents a CF 3  group; and when n is 2 or 3: 
     X or Z represents an alkoxy group from 1 to 4 carbon atoms or Y represents the CF 3  or NO 2  group. 
     The new industrial products according to the invention, which have just been defined, correspond to the G1bis group of medicaments above defined. 
     Preferred classes of compounds according to the invention are constituted by compounds corresponding to G1 to G9 groups above defined, in the framework of the medicaments and in which, when n is 1 , Y or W represents CF 3 , and when n is 2 or 3, either X or Z represents OR 1  or Y or W represents CF 3  or NO 2 . 
     Another preferred class of compounds according to the invention is constituted by the compounds of formula (X) hereabove mentioned, in which n is 2 or 3, Z represents H or OCH 3 , and W represents H, Cl or OCH 3 . 
     Another preferred class of compounds according to the invention is constituted by compounds of formulae (XI), (XII), (XIII), (XIV), (XV), (XVI) above represented and in which n is 2 or 3. 
     A group of preferred compounds is constituted by those of formula: 
     
         ______________________________________                                    
                  Compounds n°                                     
______________________________________                                    
 ##STR30##          1 043                                                 
 ##STR31##          1 276                                                 
 ##STR32##          1 277                                                 
 ##STR33##          1 417                                                 
 ##STR34##          1 418                                                 
 ##STR35##          1 419                                                 
______________________________________                                    
 
    
    
    
     SYNTHESIS OF THE COMPOUNDS WHICH ARE THE ACTIVE SUBSTANCE OF MEDICAMENTS ACCORDING TO THE INVENTION AS WELL AS NEW COMPOUNDS ACCORDING TO THE INVENTION 
     The compounds of formula (I) may be obtained by cyclization of benzenesulfonamidoacid of formula (XVII): ##STR36## in which X, Y, Z, W, n, R 1  and R 2  have the previously indicated meanings. 
     Cyclization of benzenesulfonamides can be done by using a cyclizing agent, in an acid medium, and by heating. For example P 2  O 5  can be used as a cyclizing agent and H 3  PO 4  as an acid. 
     This method of preparing the compounds of formula (I) will be denoted by Method A. 
     The compounds according to the invention which can be prepared by this method A are those in which n is 1, R 2  represents hydrogen, and X, Y, Z and W are all different from an alkoxy group. 
     Below is given a general example of practising method A to obtain the compounds of formula (I). ##STR37## 
     To 10 ml of 85% of orthophosphoric acid are added with care, 20 g of phosphoric anhydride and then 0.01 mole of a benzenesulfonamido-acid derivative. The reaction mixture is brought for 30 minutes to 3 hours to a temperature comprised between 40° and 90° C., according to the products, and then poured on cracked ice. The crystals are dried, washed abundantly with water, then with a N sodium bicarbonate solution. 
     The product is then recrystallized in the usual appropriate solvents. 
     The yield is from 60 to 90%. 
     The cyclizing of benzenesulfonamido-acids of formula (XVII) may also advantageously be effected by resorting to trifluoroacetic anhydride as cyclizing agent, in the presence of sodium trifluoroacetate and by heating it. 
     This method of production of compounds of formula (I) will be denoted in the following by Method B. 
     This method B has the advantage of being usuable for the preparation of any compounds of formula (I), and of providing a good yield. 
     Method B is preferably used when R 2  represents OH or OCOCH 3 . 
     A general example of practising method B to obtain the compounds of formula (I) is given below: ##STR38## 
     0.01 mole of benzenesulfonamido-acid derivative and 0.5 g of anhydrous sodium trifluoroacetate are brought to reflux with stirring in 20 ml of trifluoroacetic anhydride for 2 to 24 hours. 
     After evaporation of the reaction medium under vacuum, the residue is taken up again in 20 ml of anhydrous methanol and then brought to reflux for 30 minutes. The methanol solution is evaporated to dryness, and the residue is taken up in 10 ml of water. 
     The crystals are dried, then recrystallized in suitable organic solvents. 
     The yield is of from 65 to 90%. 
     The benzenesulfonamido-acids used are prepared as indicated in French patent application Nos. 81 11858 and 81 11859. 
     As regards the benzenesulfonamido-acids in which R 2  represents OH and n, R 1 , X, Y, Z, W have the above indicated meanings, they are new. 
     These new benzenesulfonamido-acids correspond to the following formula (XVIIa): ##STR39## 
     These compounds can be prepared by condensing a sulfohalogenide, particularly the sulfochloride of the formula (XVIII): ##STR40## with an aminoacid of the formula: ##STR41## by methods such as described in French patent application Nos. 81 11858 and 81 11859. 
     The preparation of the compound of formula is given below by way of example: ##STR42## 
     To 3.57 g (0.030 moles) of dl 4-amino-3-hydroxy butyric acid in 60 ml of N soda, is added drop by drop with vigourous stirring a solution of 9.4 g (0.030 moles) of 3,5-ditrifluoromethyl-benzenesulfonyl chloride in 60 ml of ethyl ether. 
     After 4 hours of stirring, the organic phase is removed. The aqueous phase is then brought to pH 3 with 2N hydrochloric acid. The precipitate formed is drained, washed with water until the disappearance of the chloride ions, then dried. 
     M. P.=160° C.; Yield=58%; m. w.=395.29. 
     Theoretical analysis for C 12  H 11  F 6  NO 5  S Calculated: C 36.4; H 2.8; N 3.6; Found: C 36.3; H 3.1; N 3.8. 
     There are also prepared by this process, compounds of the formula: ##STR43## in which Z represents Cl and W represents H and Z represents H and W represents H. 
     The compounds of formula (I) according to the invention may also be prepared by condensation of sulfohalogenides, particularly sulfochlorides, of formula (XVIII): ##STR44## in which X, Y, Z and W have the above indicated meanings with the compounds of the formula (XIX): ##STR45## in which R 1 , R 2  and n have the above indicated meanings. 
     This reaction is preferably carried out in the presence of a strong base, to take the proton from the compound (XIX), such as sodium hydride, in a solvent such as xylene and then under the effect of heating, condensation takes place. 
     This method will be denoted below by Method C. 
     The compounds according to the invention which can be prepared by this method are those in which R 2  represents hydrogen. Below is given a general example of the practising of method C. ##STR46## 
     To 0.01 mole of sodium hydride in 50 ml of anhydrous xylene, is added drop by drop 0.01 mole of the lactam derivative, under stirring. The reaction medium is brought for 2 hours to 80° C. After cooling, 0.01 mole of the appropriate sulfochloride is added drop by drop and the reaction medium is brought to 110° C. for 2 to 8 hours. 
     After removal of the solvent by distillation under vacuum, the residue is taken up again in water. The precipitate is drained, washed with water, then recrystallized in the usual solvents. 
     The yield is from 10% to 50%. 
     The sulfochlorides used for practising method C are those described in the literature as well as in the patents and patent applications in France Nos. 2 313 918, 2 338 929, 2 504 528, 2 504 527. 
     The products which have been prepared by method A are the following ones: Nos. 1 043, 1 289, 1 277, 1 276, 1 355, 1 351, 1 416, 1 039. 
     The products which have been prepared by method B are the following ones: Nos. 1 043, 1 289, 1 277, 1 276, 1 355, 1 351, 1 416, 1 419, 1 417, 1 418, 1 415, 1 120, 1 287, 1 288, 1 124, 1 285, 1 286, 1 309, 1 332, 1 310, 1 281, 1 282, 1 442, 1 441, 1 039. 
     The products which have been prepared by method C are the following ones: Nos. 1 043, 1 289, 1 277, 1 276, 1 355, 1 351, 1 416, 1 120, 1 287, 1 288, 1 124, 1 285, 1 286, 1 309, 1 332, 1 310, 1 281, 1 442, 1 441. 
     The table below gathers the compounds prepared by methods A, B and C and indicates for each of them the formula, the melting point and the yield. 
     The percent analysis of the products obtained is in accordance with the usual standards (±0.3%). 
     
         __________________________________________________________________________
GENERAL FORMULA                                                           
 ##STR47##                                                                
Compound                                     M.P.                         
No.   X   Y  Z   W   n R.sub.1                                            
                          R.sub.2                                         
                                Empirical formula                         
                                         M.W.                             
                                             °C.                   
                                                Yield                     
__________________________________________________________________________
1043  H   CF.sub.3                                                        
             H   H   1 H  H     C.sub.11 H.sub.10 F.sub.3 NO.sub.3        
                                         293.27                           
                                              74                          
                                                85                        
1289  H   CF.sub.3                                                        
             H   H   2 H  H     C.sub.12 H.sub.12 F.sub.3 NO.sub.3        
                                         307.30                           
                                              68                          
                                                75                        
1277  H   CF.sub.3                                                        
             H   H   3 H  H     C.sub.13 H.sub.14 F.sub.3 NO.sub.3        
                                         321.33                           
                                              78                          
                                                40                        
1276  H   CF.sub.3                                                        
             H   H   1 CH.sub.3                                           
                          H     C.sub.12 H.sub. 12 F.sub.3 NO.sub.3       
                                         307.30                           
                                             103                          
                                                35                        
1355  H   CF.sub.3                                                        
             Cl  H   1 H  H     C.sub.11 H.sub.9 CIF.sub.3 NO.sub.3       
                                         327.72                           
                                             118                          
                                                91                        
1351  H   CF.sub.3                                                        
             H   CF.sub.3                                                 
                     1 H  H     C.sub.12 H.sub.9 F.sub.6 NO.sub.3         
                                         361.26                           
                                             121                          
                                                76                        
1416  H   CF.sub.3                                                        
             H   CF.sub.3                                                 
                     2 H  H     C.sub.13 H.sub.11 F.sub.6 NO.sub.3        
                                         375.30                           
                                             140                          
                                                86                        
1419  H   CF.sub.3                                                        
             H   H   1 H  OH    C.sub.11 H.sub.10 F.sub.3 NO.sub.4        
                                         309.27                           
                                             100                          
                                                64                        
1417  H   CF.sub.3                                                        
             Cl  H   1 H  OH    C.sub.11 H.sub.9 ClF.sub.3 NO.sub.4       
                                         343.72                           
                                             126                          
                                                70                        
1418  H   CF.sub.3                                                        
             H   CF.sub.3                                                 
                     1 H  OH    C.sub.12 H.sub.9 F.sub.6 NO.sub.4         
                                         377.26                           
                                             120                          
                                                66                        
1415  H   CF H   CF.sub.3                                                 
                     1 H  OCOCH.sub.3                                     
                                C.sub.14 H.sub.11 F.sub.6 NO.sub.5        
                                         419.31                           
                                             105                          
                                                75                        
1120  H   H  OCH.sub.3                                                    
                 H   1 H  H     C.sub.11 H.sub.13 NO.sub.4 S              
                                         255.30                           
                                             134                          
                                                75                        
1287  H   H  OCH.sub.3                                                    
                 H   2 H  H     C.sub.12 H.sub.15 NO.sub.4 S              
                                         269.32                           
                                             105                          
                                                60                        
1288  H   H  OCH.sub.3                                                    
                 H   1 CH.sub.3                                           
                          H     C.sub.12 H.sub.15 NO.sub.4 S              
                                         269.32                           
                                             113                          
                                                45                        
1124  OCH.sub.3                                                           
          H  H   Cl  1 H  H     C.sub.11 H.sub.12 ClNO.sub.4 S            
                                         289.75                           
                                             148                          
                                                50                        
1285  OCH.sub.3                                                           
          H  H   Cl  1 CH.sub.3                                           
                          H     C.sub.12 H.sub.14 ClNO.sub.4 S            
                                         303.77                           
                                             126                          
                                                45                        
1286  OCH.sub.3                                                           
          H  H   Cl  3 H  H     C.sub.13 H.sub.16 ClNO.sub.4 S            
                                         317.80                           
                                             160                          
                                                30                        
1309  OCH.sub.3                                                           
          H  OCH.sub.3                                                    
                 OCH.sub.3                                                
                     1 H  H     C.sub.13 H.sub.17 NO.sub.6 S              
                                         315.35                           
                                             168                          
                                                45                        
1332  OCH.sub.3                                                           
          H  OCH.sub.3                                                    
                 OCH.sub.3                                                
                     1 CH.sub.3                                           
                          H     C.sub.14 H.sub.19 NO.sub.6 S              
                                         329.38                           
                                             147                          
                                                40                        
1310  OCH.sub.3                                                           
          H  OCH.sub.3                                                    
                 Cl  1 H  H     C.sub.12 H.sub.14 ClNO.sub.5 S            
                                         319.77                           
                                             173                          
                                                60                        
1281  OCH.sub.3                                                           
          H  OCH.sub.3                                                    
                 Cl  1 CH.sub.3                                           
                          H     C.sub.13 H.sub.16 ClNO.sub.5 S            
                                         333.80                           
                                             152                          
                                                55                        
1282  OCH.sub.3                                                           
          H  OCH.sub.3                                                    
                 Cl  3 H  H     C.sub.14 H.sub.18 ClNO.sub.5 S            
                                         347.83                           
                                             160                          
                                                60                        
1458  OCH.sub.3                                                           
          H  OCH.sub.3                                                    
                 H   1 CH.sub.3                                           
                          H     C.sub.13 H.sub.17 NO.sub.5 S              
                                         299.35                           
                                             151                          
                                                45                        
1459  OCH.sub.3                                                           
          H  OCH.sub.3                                                    
                 H   1 H  H     C.sub.12 H.sub.15 NO.sub.5 S              
                                         285.32                           
                                             137                          
                                                40                        
1039  H   NO.sub.2                                                        
             H   H   1 H  H     C.sub.10 H.sub.10 N.sub.2 O.sub.5         
                                         270.27                           
                                             173                          
                                                85                        
__________________________________________________________________________
 
    
     The compounds according to the invention have remarkable pharmacological properties. 
     The compounds according to the invention have psychotropic properties with modifications of the behaviour. 
     These pharmacological properties have been studied by taking aniracetam as a reference substance. 
     The compounds according to the invention are advantageously introduced as active substance, particularly in the treatment of disorders of the memory, of amnesia, in the case of physical and intellectual efforts associated with periods of overactivity, in the treatment of disorders of behaviour and of adaptation. 
     The compounds according to the invention are distinguished by the fact that they act on the memory and the attention, increasing the mental activity and equilibrating emotional behaviour. 
     The compounds according to the invention are conditioned for this purpose with the traditional excipients and adjuvants, particularly those used for the preparation of tablets, powders, capsules, drinkable ampullae, drinkable solutions, injectable solutions. 
     The administration of medicaments containing the compounds according to the invention is effected preferably by the oral route, and the doses of compounds administered are comprised from 50 to 3 000 mg/day, preferably from 200 to 2 000 mg/day, for example 100 to 1 000 mg/day, in one or several doses. 
     An example of advantageous pharmaceutical composition is constituted by a tablet or a capsule corresponding to unit dosage of 25 to 200 mg of active substance, preferably 100 mg, in association with a pharmaceutically acceptable carrier. 
     Another example of advantageous pharmaceutical composition is constituted by a drinkable solution suitable with unit dosage of 25 to 200 mg of active substance. 
     I STUDY RELATING TO THE TOXICITY 
     The compounds according to the invention are devoid of toxicity. 
     In fact, the value of the LD 50  obtained with compounds Nos. 1 039, 1 043, 1 276, 1 288, administered intraperitoneally in the mouse, is higher than 1 g/kg, which shows that at the doses administered, the compounds of the invention are not toxic. 
     II STUDY OF THE CENTRAL NERVOUS SYSTEM 
     One resorts to a device constituted by a twopart cage, formed from a lit compartment and a dark compartment, separated by a partition pierced by a passage. The floor of the dark sector is formed by an electricifiable grid. 
     After familiarization with the device, albino mice underwent one by one the initiation session: each mouse was placed in the lit cmpartment; its spontaneous latency to enter the dark compartment (preferred spontaneously) was measured; as soon as it had entered, it received an electric shock. 
     After 10 minutes (protocol A), the animal was replaced in the lit compartment. 
     The effect is evaluated by the increase of the latency to enter the dark compartment, or the time passed in the same sector and study of its behaviour in each sector. 
     The products were administered intraperitoneously at 50 mg/kg in 2% of arabic gum, 20 minutes prior (procotol A) to the initiation session. 
     The placebo was constituted by 2% arabic gum. 
     The results relating to protocol A are given in table 2. 
     
                       TABLE 2                                                     
______________________________________                                    
PROTOCOL A                                                                
              Latency to enter                                            
                           Times spent in the                             
       Number the dark compart-                                           
                           dark compartment                               
       of     ment at the initia-                                         
                           during the 3 mn of                             
       animals                                                            
              tion session the retention session                          
______________________________________                                    
PLACEBO  17       29,1 ± 6,1                                           
                               20,3 ± 7,9                              
No 1039  16       40,9 ± 8,6                                           
                               38,7 ± 7,9                              
No 1048  19       54,6 ± 8,4                                           
                               30,3 ± 9,5                              
No 1120  17       34,5 ± 5,9                                           
                               24,5 ± 9,8                              
No 1351  18        59,6 ± 12,2                                         
                               30,1 ± 9,2                              
No 1355  18       45,11 ± 7,8                                          
                               33,9 ± 9,3                              
ANIRACE- 16       45,2 ± 9,2                                           
                               22,8 ± 9,4                              
TAM                                                                       
______________________________________                                    
 
    
     The study of the behaviour of the mice shows that their exploratory capacity is increased in the two sectors, which is manifested by an increase in the latency of entry into the dark sector and an increase of the time passed in the dark sector. 
     III STUDY OF MOTOR ACTIVITY BY MEANS OF THE TEST CALLED &#34;OPEN FIELD TEST&#34; 
     This relates to a test recommended by JANSSEN et al. (&#34;Psychopharmacologia&#34;, 1960, 1, p. 389-392) improved for the measurement of motor activity by an automatic apparatus by DELBENE et al. (&#34;Psychologia&#34;, 1970, 18, p. 227-230). 
     This test has been adapted by G. NARCISSE et al. (unpublished work). 
     The doses were 50 and 100 mg/kg intraperitoneally. 
     This test carried out with compound No. 1 039 shows that this compound has psychotropic properties. This test, carried out under the same conditions with the compounds of the invention No. 1 403, 1 276, 1 277, 1 281, 1 288, 1 309, 1 417, 1 418 and 1 419, shows that these compounds also have a psychotropic activity.